# Clinical Trials Data KIT - Document 18

# Cluster RCT - Evaluating Effectiveness of a Guide and Tools for Influenza Immunization Campaign Planners

## Clinical Trial: https://clinicaltrials.gov/study/NCT01207518

"eligibilityCriteria": "Inclusion Criteria:\n\nAt least 46 healthcare organizations from across Canada will be selected to participate in the study.\n\nThe Guide is designed to be used across different types of healthcare organizations. Potential healthcare organizations will be self-identified, recommended by a project team member, and/or selected from the Canadian Healthcare Association's Guide to Healthcare Facilities. Selected sites must meet the following eligibility criteria:\n\n\* Canadian healthcare organizations who conduct seasonal influenza immunization campaigns\n\* Have a systematic approach to collecting healthcare personnel immunization rates and be able to provide accurate and timely reports of immunization rates for categories of healthcare personnel\n\* Agree to be randomized to receive the Guide or receive no intervention\n\* If randomized to receive the Guide, the organization, including the campaign team and senior management, agrees to commit to adhere to the steps in the Guide to plan, implement, monitor and evaluate their campaign\n\nExclusion Criteria:\n\nHealthcare organizations who do not meet the above criteria",  
 "healthyVolunteers": true,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a KIT gene mutation be eligible for the clinical trial?

Answer:  
The clinical trial information you provided appears to be about a study involving healthcare organizations in Canada and their influenza immunization campaigns. The eligibility and exclusion criteria are specific to healthcare organizations and not individual patients. Therefore, the presence of a KIT gene mutation in a patient would not be relevant to the eligibility criteria for this particular trial. It seems that individual patients, including those with specific mutations, are not the target of this clinical trial's inclusion or exclusion criteria.